Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Olema Pharmaceuticals, Inc. (OLMA : NSDQ)

• Company Description    Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California. Number of Employees: 96

• Price / Volume Information    Yesterday's Closing Price: $33.05 Daily Weekly Monthly 20 Day Moving Average: 8,400,722 shares Shares Outstanding: 68.66 (millions) Market Capitalization: $2,269.21 (millions) Beta: 1.87 52 Week High: $33.50 52 Week Low: $2.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 316.25% 310.76% 12 Week 288.37% 277.25% Year To Date 466.90% 361.67%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 780 Brannan Street - San Francisco,CA 94103 USA ph: 415-651-3316 fax: - ir@olema.com http://www.olema.com

• General Corporate Information    Officers Sean Bohen - President and Chief Executive Officer Shane Kovacs - Chief Operating and Financial Officer Ian Clark - Director Cynthia Butitta - Director Cyrus L. Harmon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68062P106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/17/26 Share - Related Items Shares Outstanding: 68.66 Most Recent Split Date: (:1) Beta: 1.87 Market Capitalization: $2,269.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.53 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.89 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/17/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.38 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 18.33% vs. Previous Quarter: 3.92% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -41.56 06/30/25 - -42.58 03/31/25 - -42.31 ROA 09/30/25 - -37.65 06/30/25 - -38.65 03/31/25 - -38.32 Current Ratio 09/30/25 - 8.03 06/30/25 - 11.09 03/31/25 - 15.22 Quick Ratio 09/30/25 - 8.03 06/30/25 - 11.09 03/31/25 - 15.22 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 4.48 06/30/25 - 5.05 03/31/25 - 5.61 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.01 06/30/25 - 0.01 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.97 06/30/25 - 0.86 03/31/25 - 0.00

Powered by Zacks Investment Research ©